Research programme: antiviral vaccines - Profectus BioSciences

Drug Profile

Research programme: antiviral vaccines - Profectus BioSciences

Alternative Names: Chikungunya virus vaccine - Profectus; filovirus MCM - Profectus; HCV vaccine - Profectus BioSciences; HPV vaccine - Profectus BioSciences; HSV vaccine - Profectus BioSciences; Lassa fever vaccine - Profectus; Preventative HIV rVSV vaccine - Profectus; rVSV Marburg vaccine; rVSV-Ebola vaccine - Profectus; rVSVN4CT1 Z Ebola; VesiculoVax rVSV-vectored Ebola/Marburg vaccine; VesiculoVax™-EEEV; VesiculoVax™-VEEV; Z EboV rVSVN4CT1

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Profectus Biosciences
  • Developer Profectus Biosciences; University of Texas Medical Branch
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Ebola virus infections; Encephalitis; Marburg virus disease; Viral infections; Zika virus infection
  • Research Lassa fever

Most Recent Events

  • 02 Oct 2017 Profectus BioSciences plans a phase I trial for the treatment of Ebola, Marburg, and Lassa virus infections
  • 20 Jan 2017 Preclinical development is ongoing in Marburg virus disease(Prevention) in USA (IM, Injection) (Profectus Biosciences pipeline, January 2017)
  • 20 Jan 2017 Preclinical development is ongoing in Viral-infections in USA (Parenteral) (Profectus Biosciences pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top